Email this article 
Use of oral anticoagulants after intramedullary nailing of femur and tibial fractures in trauma department
- Authors: Dulaev A.K.1, Tsed A.N.1, Dzhusoev I.G.1
-
Affiliations:
- Dzhanelidze Saint-Petersburg Research Institute of Emergency Medicine
- Issue: Vol 20, No 4 (2014)
- Pages: 99-103
- Section: Experience exchange
- Submitted: 12.09.2016
- Published: 12.12.2014
- URL: https://journal.rniito.org/jour/article/view/104
- DOI: https://doi.org/10.21823/2311-2905-104
- ID: 104
Cite item
Full Text
Abstract
The authors evaluated of the effectiveness of new oral anticoagulants in patients with diaphyseal fractures of the femur and tibia.We analyzed the effectiveness of thromboprophylaxis in 85 patients with diaphyseal fractures of the femur and tibia in the early postoperative period. Patients were divided into 3 groups: group 1 - patients, who was taking enoxaparin, group 2 - dabigatran etexilate, group 3 - rivaroxaban. We evaluated the frequency of thromboembolic complications and bleeding for 4 weeks after intramedullary nailing of femur and tibia.The lowest frequency of postoperative bleeding was observed in patients treated with dabigatran etexilate. In addition, the minimum frequency of complications was observed among patients of the second group of the study (9.7% in the group receiving dabigatran etexilati compared with 27.8% for the combined group I and III).Statistically significant differences between groups of patients taking oral or parenteral anticoagulants was not obtained.
About the authors
A. K. Dulaev
Dzhanelidze Saint-Petersburg Research Institute of Emergency Medicine
Author for correspondence.
Email: noemail@neicon.ru
Россия
A. N. Tsed
Dzhanelidze Saint-Petersburg Research Institute of Emergency Medicine
Email: tsed@mail.ru
Россия
I. G. Dzhusoev
Dzhanelidze Saint-Petersburg Research Institute of Emergency Medicine
Email: noemail@neicon.ru
Россия
References
- Баркаган З.С. Пути совершенствования и пролонгации антитромбической профилактики и терапии (систематический обзор и итоги 50-летнего личного опыта автора). Гематология и трансфузиология. 2005; (4): 3-7.
- Заболотских И.Б., Синьков С.В. Основы гемостазиологии. Краснодар; 2002. 214 с.
- Затейщиков Д.А., Зотова И.В. Дабигатран: перспективы клинического применения. Фарматека. 2011; (15): 30-34.
- Зубаиров Д.М. Молекулярные основы свертывания крови и тромбообразования. Казань: Фэн; 2000. 364 с.
- Минасов Т.Б., Минасов Б.Ш., Загидуллин Ш.З., Загидуллин Н.Ш., Каглаян Е., Гассанов Н. Дабигатран - новый подход к профилактике тромбоэмболических осложнений. Травматология и ортопедия России. 2011; (3): 80-83.
- Тихилов Р.М., Стойко Ю.М., Замятин М.Н., Божкова С.А. Профилактика тромбоэмболических осложнений в травматологии и ортопедии. Методические рекомендации под редакцией академика РАМН Ю. Л. Шевченко. М.; 2006. 20 с.
- Blommel M.L., Blommel A.L. Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Health Syst Pharm. 2011; 68 (16): 1506-1519.
- Eriksson В. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370: 949-956.
- Lindblad B., Sternby N.H., Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J. 1991; 302: 709-711.
- Nordstrom M., Lindblad B., Bergqvist D. et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992; 232: 155-160.
- Turpie A.G. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vase Biol. 2007; 27:1238-1247.
- Verlato F., Bruchi O., Prandoni P. et al. The value of ultrasound screening for proximal vein thrombosis after total hip arthroplasty a prospective cohort study. Thromb Haemost. 2001; 86: 534-537.
Supplementary files
